#USA #Chicago #MammoScreen #Therapixel #Onsite Health

Therapixel and Onsite Women's Health Collaboration

In a groundbreaking initiative aimed at enhancing breast cancer detection and patient outcomes, Therapixel has announced a strategic partnership with Onsite Women's Health. This collaboration introduces the use of MammoScreen®, an advanced artificial intelligence (AI) solution, across Onsite's extensive network of over 150 locations nationwide. The partnership underscores the commitment of both organizations to leverage cutting-edge technology to improve the early detection of breast cancer and elevate the standard of care for women.

Advancing Patient Care with AI

Therapixel, known for its innovative contributions to medical imaging, has developed MammoScreen® to assist radiologists in identifying subtle abnormalities in breast tissue that could be indicative of cancer. This AI-driven tool is not only designed to enhance diagnostic accuracy but also to assist in significantly reducing the workload and fatigue often experienced by radiologists. It offers support in recognizing critical signs of breast cancer earlier than traditional methods, thus fostering a more proactive approach to breast health.

According to Matthieu Leclerc-Chalvet, CEO of Therapixel, the integration of MammoScreen into Onsite Women's Health’s workflow is a significant advancement in their mission to provide lifesaving technology to women across the United States. He emphasizes the impact of this technology on the speed and accuracy of cancer screening, which is paramount in improving outcomes for patients.

Onsite Women’s Health, a leader in in-office breast health services, shares this vision. Jillian Wright, the company’s CEO, expressed excitement about the partnership, highlighting the importance of equipping radiologists with top-of-the-line technology. This integration aims to ensure that patients receive the highest quality care and that breast cancer is detected as early as possible, thereby saving more lives.

MammoScreen’s Capabilities

MammoScreen employs deep learning algorithms to sift through extensive imaging data, highlighting abnormalities that may be overlooked during standard reviews. Studies show that it can detect approximately 42% of cancers a year prior to clinical diagnosis and 38.5% two years before. Furthermore, the tool enhances diagnostic consistency and equity in patient care, reducing variability among different radiologists. With a focus on increasing specificity, MammoScreen also minimizes unnecessary patient recalls, thus alleviating anxiety and streamlining the patient experience.

Onsite radiologists and partner practices that utilize MammoScreen can expect to benefit from increased diagnostic confidence and improved operational efficiency. These enhancements are not just about faster results; they aim at fostering a more patient-centric approach in breast health services where high-quality care is the norm.

A Shared Vision for Women's Health

The partnership is defined by a collective aspiration to elevate healthcare standards for women, making vital breast health screenings more accessible and personalized. Both Therapixel and Onsite are committed to using advanced AI technologies to transform breast cancer detection, ensuring that women receive timely and accurate diagnoses. The collaboration represents a significant step towards addressing the critical issue of breast cancer, which affects countless women every year.

In conclusion, the alliance between Therapixel and Onsite Women's Health exemplifies how innovative technology and healthcare services can work hand-in-hand to enhance patient care. By harnessing the capabilities of MammoScreen, they are not only improving existing processes but also paving the way for future advancements in breast health care—underscoring the profound impact of artificial intelligence in the medical field.

About Onsite Women's Health

Onsite Women's Health provides a broad range of in-office breast health and imaging services, including 3D mammography and breast ultrasounds, dedicated to increasing compliance in screening practices and improving detection rates. By integrating innovative technology, they are reshaping how breast care is delivered across the United States.

About Therapixel

As a pioneer in the medical imaging domain, Therapixel is dedicated to enhancing diagnostic accuracy and workflow efficiency through AI solutions. Their ongoing efforts in innovation aim to support healthcare professionals in identifying breast cancer earlier and more effectively.